Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo

Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo

The rVSVΔG-ZEBOV-GP vaccine constitutes a valuable tool to control Ebola virus disease outbreaks. This retrospective cohort study aimed to assess the protective effect of the vaccine against death among patients with confirmed Ebola virus disease. In this retrospective cohort analysis of patients wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet infectious diseases 2024-06, Vol.24 (6), p.602-610
Hauptverfasser: Coulborn, Rebecca M, Bastard, Mathieu, Peyraud, Nicolas, Gignoux, Etienne, Luquero, Francisco, Guai, Bérengère, Bateyi Mustafa, Stephane Hans, Mukamba Musenga, Elisabeth, Ahuka-Mundeke, Steve
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Adult
Child
Clinical medicine
Cohort analysis
Death
Democratic Republic of the Congo - epidemiology
Disease control
Ebola Vaccines - administration & dosage
Ebola Vaccines - immunology
Ebola virus
Ebolavirus
Ebolavirus - immunology
Epidemics
Fatalities
Female
Glycoproteins
Health care access
Health care facilities
Health facilities
Health risks
Hemorrhagic Fever, Ebola - epidemiology
Hemorrhagic Fever, Ebola - mortality
Hemorrhagic Fever, Ebola - prevention & control
Humans
Immunization
Infections
Laboratories
Male
Middle Aged
Mortality
Observational studies
Retrospective Studies
Risk Factors
Translation
Vaccination
Vaccines
Viral diseases
Viremia
Viruses
Young Adult
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The rVSVΔG-ZEBOV-GP vaccine constitutes a valuable tool to control Ebola virus disease outbreaks. This retrospective cohort study aimed to assess the protective effect of the vaccine against death among patients with confirmed Ebola virus disease. In this retrospective cohort analysis of patients with confirmed Ebola virus disease admitted to Ebola health facilities in the Democratic Republic of the Congo between July 27, 2018, and April 27, 2020, we performed univariate and multivariate analyses to assess case fatality risk and cycle threshold for nucleoprotein according to vaccination status, Ebola virus disease-specific treatments (eg, mAb114 and REGN-EB3), and other risk factors. We analysed all 2279 patients with confirmed Ebola virus disease. Of these 2279 patients, 1300 (57%) were female and 979 (43%) were male. Vaccination significantly lowered case fatality risk (vaccinated: 25% [106/423] vs not vaccinated: 56% [570/1015]; p
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(23)00819-8